Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, Thomas F., Zhao, Fangzhu, Huang, Deli, Beutler, Nathan, Burns, Alison, He, Wan-ting, Limbo, Oliver, Smith, Chloe +26 more·2020·Science
DOI 10.1126/science.abc7520

Cited by (1,034)

Items 501–600 of 1,034

  1. Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
    Jennifer Serwanga, Violet Ankunda, Jackson Sembera, Laban Kato, Gerald Kevin Oluka, Claire Baine, Geoffrey Odoch, John Timothy Kayiwa, Betty Oliver Auma, Mark Jjuuko et al. · 2023 · Frontiers in Immunology
  2. Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
    Giuseppe A. Palumbo, Daniela Cambria, Enrico La Spina, Andrea Duminuco, Antonio Laneri, Anna Longo, Calogero Vetro, Sebastiano Giallongo, Alessandra Romano, Francesco Di Raimondo et al. · 2023 · Frontiers in Oncology
  3. Antibody-mediated immunity to SARS-CoV-2 spike
    John M. Errico, Lucas J. Adams, Daved H. Fremont · 2022 · Advances in immunology
  4. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants
    Akitsu Masuda, Jae Man Lee, T. Miyata, H. Mon, Keita Sato, Kosuke Oyama, Yasuteru Sakurai, J. Yasuda, Daisuke Takahashi, T. Ueda et al. · 2022 · Frontiers in Immunology
  5. Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects
    A. Manenti, Elena Gianchecchi, F. Dapporto, Margherita Leonardi, Paolo Cantaloni, F. Fattorini, Pietro Piu, V. Bollati, U. Pastorino, G. Apolone et al. · 2021 · JIM - Journal of Immunological Methods
  6. Structure-guided antibody cocktail for prevention and treatment of COVID-19
    Shih-Chieh Su, Tzu‐Jing Yang, Pei‐Yu Yu, Kang-Hao Liang, Chen Wy, Chun-Wei Yang, Hsiu-Ting Lin, Mei-jung Sebrina Wang, Ruei‐Min Lu, Hsien-Cheng Tso et al. · 2021 · PLoS Pathogens
  7. Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)
    Xilin Wu, Yaxin Wang, Lin Cheng, Fengfeng Ni, Linjing Zhu, Sen Ma, Bilian Huang, Mengmeng Ji, Huimin Hu, Yuncheng Li et al. · 2022 · Frontiers in Immunology
  8. Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
    Rakesh Kulkarni, Wen-Ching Chen, Ying Lee, Chi‐Fei Kao, Shiu-Lok Hu, Hsiu‐Hua Ma, Jia‐Tsrong Jan, Chun‐Che Liao, Jian‐Jong Liang, Hui‐Ying Ko et al. · 2021 · PLoS ONE
  9. Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition
    Lorenzo Di Rienzo, Michele Monti, E. Milanetti, Mattia Miotto, A. Boffi, G. Tartaglia, G. Ruocco · 2021 · Computational and Structural Biotechnology Journal
  10. Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection
    Rachel R. Yuen, Dylan Steiner, Riley M.F. Pihl, Elizabeth C. Chavez, Alex Olson, Erika L. Smith-Mahoney, Lillia A. Baird, Filiz T. Korkmaz, Patricia Urick, Manish Sagar et al. · 2021 · Frontiers in Immunology
  11. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
    A. Walls, Marcos C. Miranda, Minh N. Pham, A. Schäfer, Allison J. Greaney, Prabhu S. Arunachalam, M. Navarro, M. A. Tortorici, Kenneth A. Rogers, Megan A. O'Connor et al. · 2021 · bioRxiv
  12. Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Infection as an Innate Antiviral Mechanism
    Lamiaa El-Shennawy, Andrew D. Hoffmann, Nurmaa K. Dashzeveg, P. Mehl, Zihao Yu, V. Tokars, V. Nicolaescu, Carolina Ostiguin, Y. Jia, Lin Li et al. · 2020 · bioRxiv
  13. Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein
    Wang, Chunyan, van Haperen, Rien, Gutiérrez-Álvarez, Javier, Li, Wentao, Okba, Nisreen M.A., Albulescu, Irina, Widjaja, Ivy, van Dieren, Brenda, Fernandez-Delgado, Raul, Sola, Isabel et al. · 2020
  14. Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
    D. Sheward, Pradeepa Pushparaj, H. Das, Allison J. Greaney, Changil Kim, Sungyong Kim, L. Hanke, Erik Hyllner, R. Dyrdak, Ji-Min Lee et al. · 2024 · Cell Reports Medicine
  15. Variants of SARS-CoV-2: Influences on the Vaccines’ Effectiveness and Possible Strategies to Overcome Their Consequences
    Ali Ahmed Rabaan, Shamsah H. Al-Ahmed, Hawra Albayat, Sara M. Alwarthan, Mashael M. Alhajri, Mustafa A. Najim, Bashayer Mohammed Alshehail, Wasl Al-Adsani, Ali Alghadeer, Wesam A. Abduljabbar et al. · 2023 · Medicina
  16. Essential oils block cellular entry of SARS-CoV-2 delta variant
    Luiz Torres Neto, Maria Lúcia Guerra Monteiro, José A. Fernández-Romero, Natalia Teleshova, James Sailer, Carlos Adam Conte‐Júnior · 2022 · Scientific Reports
  17. Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals
    Mariliis Jaago, Annika Rähni, Nadežda Pupina, Arno Pihlak, Helle Sadam, Jürgen Tuvikene, Annela Avarlaid, Anu Planken, Margus Planken, Liina Haring et al. · 2022 · Scientific Reports
  18. Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses
    Per Johan Klasse, John P. Moore · 2022 · Journal of Virology
  19. Protein engineering responses to the COVID-19 pandemic
    Ching-Lin Hsieh, J. McLellan · 2022 · Current Opinion in Structural Biology
  20. Zinc and vitamin C intake increases spike and neutralising antibody production following SARS‐CoV‐2 infection
    A. Quek, D. Ooi, Ooiean Teng, Chang-Yi-En Chan, G. Ng, M. Ng, Sidney Yee, Ee Wan Cheong, Rui-Fen Weng, A. Cook et al. · 2022 · Clinical and Translational Medicine
  21. Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects
    K. Saker, B. Pozzetto, V. Escuret, V. Pitiot, A. Massardier‐Pilonchery, Bouchra Mokdad, C. Langlois-Jacques, M. Rabilloud, D. Alfaiate, Nicolas Guibert et al. · 2022 · medRxiv
  22. In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
    Silvère Pagant, Rachel A. Liberatore · 2021 · Pharmaceutics
  23. Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development
    A. Mallano, A. Ascione, M. Flego · 2021 · International Reviews of Immunology
  24. Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model
    Steven Blake, N. Shaabani, L. M. Eubanks, Junki Maruyama, John T. Manning, N. Beutler, S. Paessler, Henry Ji, J. Teijaro, K. Janda · 2021 · ACS Infectious Diseases
  25. Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus
    A. Gracheva, E. Korchevaya, A. Kudryashova, O. V. Borisova, O. Petrusha, D. Smirnova, I. Chernyshova, O. A. Svitich, V. V. Zverev, E. Faizuloev · 2021 · Journal of microbiology, epidemiology and immunobiology
  26. Decay of Fc-dependent antibody functions after mild to moderate COVID-19
    Lee, Wen Shi, Selva, Kevin John, Davis, Samantha K., Wines, Bruce D., Reynaldi, Arnold, Esterbauer, Robyn, Kelly, Hannah G., Haycroft, Ebene R., Tan, Hyon-Xhi, Juno, Jennifer A. et al. · 2020
  27. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection
    J. Guenthoer, M. Lilly, Tyler N. Starr, Bernadeta Dadonaite, Klaus N. Lovendahl, Jacob T. Croft, Caitlin I. Stoddard, V. Chohan, Shi-Lei Ding, Felicitas Ruiz et al. · 2022 · bioRxiv
  28. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor
    S. Sinha, Benjamin Tam, San Wang · 2021 · Viruses
  29. Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
    Yi-Sheng Sun, Jingjing Zhou, Han-Ping Zhu, Fang Xu, Wen-Bin Zhao, Hangjing Lu, Zhen Wang, Shu-Qing Chen, Ping-Ping Yao, Jianmin Jiang et al. · 2021 · Viruses
  30. Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection
    Zi-Jun Wang, Frauke Muecksch, Dennis J. Schaefer-Babajew, Shlomo Finkin, Charlotte Viant, C. Gaebler, H. Hoffmann, C. Barnes, M. Cipolla, Victor A. Ramos et al. · 2021 · bioRxiv
  31. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection
    A. Tabll, Y. Shahein, M. Omran, M. Elnakib, Ameera Ragheb, Khaled Amer · 2021 · Human Antibodies
  32. Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro
    Preeti Vishwakarma, Naveen Yadav, Zaigham Abbas Rizvi, N. Khan, A. Chiranjivi, Shailendra Mani, M. Bansal, Prabhanjan Dwivedi, T. Shrivastava, Rajesh Kumar et al. · 2021 · Frontiers in Immunology
  33. SARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera
    A. Kuzmina, Yara Khalaila, O. Voloshin, Ayelet Keren-Naus, Liora Bohehm, Y. Raviv, Y. Shemer-Avni, Elli Rosenberg, R. Taube · 2021 · medRxiv
  34. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
    L. Adams, Laura A. VanBlargan, Zhuo-Ming Liu, P. Gilchuk, Hai-Yan Zhao, Rita E. Chen, S. Raju, Zhen-Lu Chong, Bradley M. Whitener, S. Shrihari et al. · 2023 · Cell Reports Medicine
  35. Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
    Mingtao Liu, Hui Gan, Zhi-Man Liang, Li Liu, Qi-Wen Liu, Yiyin Mai, Hui-Huang Chen, Baoying Lei, Shangwei Yu, Hui-Hui Chen et al. · 2023 · Frontiers in Microbiology
  36. A novel plant‐made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS‐CoV‐2 Omicron variant
    Collin Jugler, Hai-Yan Sun, Katherine Nguyen, Roman Palt, M. Felder, H. Steinkellner, Qiang Chen · 2022 · Plant Biotechnology Journal
  37. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial
    T. Nguyen, Quyet Do, L. T. Phan, D. Dinh, H. Khong, L. V. Hoàng, T. V. Nguyen, H. Pham, M. Chử, T. T. Nguyễn et al. · 2022 · The Lancet Regional Health - Western Pacific
  38. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern
    Branislav Kováčech, Ľubica Fialová, Peter Filipčík, Rostislav Škrabana, Monika Žilková, Natalia Paulenka Ivanovova, Andrej Kováč, Denisa Palova, Gabriela Rolkova, Katarina Tomkova et al. · 2022 · EBioMedicine
  39. Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India
    Shubham Shrivastava, S. Palkar, J. Shah, Prajakta S. Rane, S. Lalwani, A. Mishra, V. Arankalle · 2021 · American Journal of Tropical Medicine and Hygiene
  40. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients
    Yi-Qi R. Luo, C. Yun, I. Chakraborty, A. Wu, K. Lynch · 2021 · Journal of Clinical Microbiology
  41. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization
    Maggie Gu, J. Torres, Yi-Jia Li, Alex Van Ry, Jack Greenhouse, Shannon E. Wallace, Chi-I Chiang, Laurent Pessaint, A. Jackson, Maciel Porto et al. · 2021 · Emerging Microbes and Infections
  42. Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: Progress, evidence gaps, and translational pathways for durable and scalable immunization
    Ugwu Okechukwu Paul-Chima, Michael Ben Okon, Ogenyi Fabian C., Ugwu Jovita Nnenna, Chinyere Nneoma Ugwu · 2026 · Human Vaccines & Immunotherapeutics
  43. Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern
    Adonis A. Rubio, Viren A. Baharani, Bernadeta Dadonaite, Megan Parada, Morgan E. Abernathy, Zijun Wang, Yu Erica Lee, Michael R. Eso, Jennie L. Phung, Israel Ramos et al. · 2025 · Science Translational Medicine
  44. Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections
    Z. Zhuang, Jianfen Zhuo, Yaochang Yuan, Zhaoming Chen, Sheng-Nan Zhang, Ai-Ru Zhu, Jing-Xian Zhao, Jin-Cun Zhao · 2024 · Vaccines
  45. From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2
    Anoop Kumar, Prajna Tripathi, Prashant Kumar, Ritu Shekhar, R. Pathak · 2024 · Vaccines
  46. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
    Chang Liu, Raksha Das, Aiste Dijokaite-Guraliuc, Da-Ming Zhou, A. Mentzer, P. Supasa, Muneeswaran Selvaraj, H. Duyvesteyn, Thomas G. Ritter, N. Temperton et al. · 2024 · Nature Communications
  47. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
    Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Armando Camacho, C. Alméciga-Díaz, Cesar A. Ramirez-Segura · 2024 · Heliyon
  48. Evolutionary trajectory of SARS-CoV-2 genome shifts during widespread vaccination and emergence of Omicron variant
    K. Gayvert, S. McKay, W. Lim, Alina Baum, Christos A. Kyratsous, R. Copin, G. Atwal · 2023 · Npj viruses
  49. Broadening a SARS-CoV-1–neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
    Fang-Zhu Zhao, M. Yuan, Celina Keating, N. Shaabani, Oliver Limbo, Collin Joyce, J. Woehl, Shawn Barman, Alison Burns, Quoc Tran et al. · 2023 · Science Signaling
  50. DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    K. Toyama, T. Eto, Kenji Takazawa, Shinji Shimizu, T. Nakayama, K. Furihata, Y. Sogawa, M. Kumazaki, Nao Jonai, Satoko Matsunaga et al. · 2023 · Vaccine
  51. Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics.
    B. Babalola, Oluwamayowa S Akinsuyi, Elizabeth Oreoluwa Folajimi, F. Olujimi, Ahmed Adebisi Otunba, Bruno Chikere, Ibitayo Ajayi Adewumagun, Tosin Emmanuel Adetobi · 2023 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  52. A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
    Naphak Modhiran, Simon Malte Lauer, Alberto Anastacio Amarilla, Peter Hewins, Sara Lopes van den Broek, Yu Shang Low, Nazia Thakur, Benjamin Liang, Guillermo Valenzuela, James Jung et al. · 2023 · iScience
  53. Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis
    María Julia Ruiz, Gabriel Siracusano, Andréa Cottignies-Calamarte, Daniela Tudor, Fernando Real, Aiwei Zhu, Claudia Pastori, Claude Capron, Arielle R. Rosenberg, Nigel James Temperton et al. · 2022 · Frontiers in Immunology
  54. Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
    M. Bhattacharya, S. Chatterjee, Bidyut Mallik, A. R. Sharma, C. Chakraborty · 2022 · Vaccines
  55. A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters
    S. Chaturvedi, N. Beutler, Gustavo Vasen, M. Pablo, Xinyue Chen, Giuliana P. Calia, Lauren Buie, R. Rodick, Davey M. Smith, T. Rogers et al. · 2022 · Proceedings of the National Academy of Sciences of the United States of America
  56. Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein
    Yu-Lei Chen, Jin-Jin Lin, Huan Ma, Ning Zhong, Xin-Xin Xie, Yunru Yang, Pei-Yi Zheng, Ling-Jing Zhang, Teng-Chuan Jin, M. Cao · 2022 · International Journal of Molecular Sciences
  57. Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection
    Lindsay Wieczorek, Michelle Zemil, Mélanie Merbah, Vincent Dussupt, Erin Kavusak, Sebastian Molnar, Jonah Heller, Bradley Beckman, Suzanne E. Wollen-Roberts, Kristina K. Peachman et al. · 2022 · Frontiers in Immunology
  58. IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes
    José Luis Velasco Garrido, Matías A. Medina, Felipe Bravo, Sarah McGee, Francisco Fuentes‐Villalobos, Mario A. Calvo, Yazmín Pinos, James W. Bowman, Christopher D. Bahl, María Inés Barría et al. · 2022 · Cell Reports
  59. Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19
    V. Botosso, S. Jorge, R. Astray, A. M. de Sá Guimarães, M. Mathor, de Carneiro Patrícia dos Santos, E. Durigon, D. Covas, D. B. D. de Oliveira, Ricardo das Neves Oliveira et al. · 2022 · Scientific Reports
  60. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
    Natasha M. Clark, S. Janaka, William Hartman, S. Stramer, E. Goodhue, J. Weiss, David T. Evans, J. Connor · 2022 · PLoS ONE
  61. Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection
    Mathilde Choteau, Anaïs Scohy, Stéphane Messe, Mathieu Luyckx, Mélanie Dechamps, Virginie Montiel, Jean Cyr Yombi, Damien Gruson, Nisha Limaye, Thomas Michiels et al. · 2022 · Scientific Reports
  62. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
    Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Bothamai Dechates, Monprach Harnphadungkit, Gaidganok Sornsamdang, Kasiruck Wittayasak, Kamonwan Soonklang, Nithi Mahanonda · 2022 · Human Vaccines & Immunotherapeutics
  63. Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2
    Rahul Ukey, N. Bruiners, Hridesh Mishra, P. Mishra, Deborah McCloskey, A. Onyuka, Fei Chen, A. Pinter, D. Weiskopf, A. Sette et al. · 2022 · BMC Medicine
  64. Investigating Constraints Along the Plant Secretory Pathway to Improve Production of a SARS-CoV-2 Spike Vaccine Candidate
    Emmanuel Margolin, M. Verbeek, Warren R. J. de Moor, R. Chapman, A. Meyers, Georgia Schäfer, A. Williamson, E. Rybicki · 2022 · Frontiers in Plant Science
  65. Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection
    L. Muir, Aneesa Jaffer, C. Rees-Spear, Vignesh Gopalan, F. Chang, R. Fernando, Gintare Vaitkute, C. Roustan, Annachiara Rosa, Christopher Earl et al. · 2021 · Kidney International Reports
  66. A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope
    Laura A. VanBlargan, L. Adams, Zhuo-Ming Liu, Rita E. Chen, P. Gilchuk, S. Raju, Brittany K. Smith, Hai-Yan Zhao, J. Case, Emma S. Winkler et al. · 2021 · bioRxiv
  67. In search for the SARS-CoV-2 protection correlate: A head-to-head comparison of two quantitative S1 assays in a group of pre-characterized oligo-/asymptomatic patients
    R. Rubio-Acero, N. Castelletti, V. Fingerle, L. Olbich, A. Bakuli, R. Woelfel, P. Girl, K. Mueller, S. Jochum, M. Strobl et al. · 2021 · medRxiv
  68. The development of neutralizing antibodies against SARS-CoV-2 and their common features
    Liu Daisy Liu, Chaoyang Lian, Leng-Siew Yeap, Fei‐Long Meng · 2020 · Journal of Molecular Cell Biology
  69. Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2
    D. Singh, Ihn Han, E. Choi, D. Yadav · 2020 · Computational and Structural Biotechnology Journal
  70. IgV somatic mutation of human anti–SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity
    de Mattos Barbosa, Mayara Garcia, Liu, Hui, Huynh, Daniel, Shelley, Greg, Keller, Evan T., Emmer, Brian T., Sherman, Emily, Ginsburg, David, Kennedy, Andrew A., Tai, Andrew W. et al. · 2021 · JCI Insight
  71. Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19
    Natalie M. Kirk, Yu-Ying Liang, H. Ly · 2024 · Virulence
  72. SARS-CoV-2 protein ORF8 limits expression levels of Spike antigen and facilitates immune evasion of infected host cells
    Ikjung Kim, Yong-Ho Lee, M. Khalid, Irene P. Chen, Yi-Ni Zhang, M. Ott, E. Verdin · 2023 · Journal of Biological Chemistry
  73. Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
    Mark Chernyshev, Mrunal Sakharkar, Ruth I. Connor, Haley L. Dugan, Daniel J. Sheward, C. Garrett Rappazzo, Aron Stålmarck, Mattias N.E. Forsell, Peter F. Wright, Martin Corcoran et al. · 2023 · Nature Communications
  74. Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes
    Jonathan Hurtado, T. Rogers, D. Jaffe, Bruce A. Adams, S. Bangaru, Elijah Garcia, Tazio Capozzola, Terrence Messmer, Pragati Sharma, G. Song et al. · 2023 · bioRxiv
  75. SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines
    O. Smirnova, O. Ivanova, I. Fedyakina, G. Yusubalieva, V. Baklaushev, D. Yanvarev, O. Kechko, V. Mitkevich, P. Vorobyev, V. Fedorov et al. · 2023 · Cancers
  76. Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
    D. Dormeshkin, M. Shapira, S. Dubovik, A. Kavaleuski, M. Katsin, A. Migas, A. Meleshko, S. Semyonov · 2022 · Frontiers in Immunology
  77. Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population
    Hee-Jung Lee, Jin Jung, Ji Hyun Lee, Dong-Gun Lee, Y. B. Kim, E. Oh · 2022 · Viruses
  78. SARS-CoV-2 spike variants differ in their allosteric responses to linoleic acid
    A. S. Oliveira, D. Shoemark, A. Davidson, I. Berger, C. Schaffitzel, A. Mulholland · 2022 · bioRxiv
  79. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies
    Ruofan Li, Michael Mor, Bingting Ma, Alex E. Clark, Joel Alter, Michal Werbner, Jamie Casey Lee, Sandra Lawrynowicz Leibel, Aaron F. Carlin, Moshe Dessau et al. · 2022 · Communications Biology
  80. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
    K. van der Straten, M. V. van Gils, S. D. de Taeye, G. D. de Bree · 2022 · Frontiers in Medical Technology
  81. SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants
    Almu’atasim Khamees, Jamal Bani-Issa, Mazhar Salim Al Zoubi, Taqwa Qasem, Manal Issam Abu Alarjah, Sura Ahmad Alawadin, Khayry Al‐Shami, F H Hussein, Emad I. Hussein, Ibrahim H. Bashayreh et al. · 2022 · Pathogens
  82. Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy
    Z. Cheng, Bi-Zhou Li, Zhi-Qing Zhan, Zi-Fan Zhao, Ming-Shan Xue, P. Zheng, Jiali Lyu, Chundi Hu, Jian-Xing He, Ru-Chong Chen et al. · 2022 · Clinical reviews in allergy and immunology
  83. Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways
    Fangzhu Zhao, Celina Keating, Gabriel Ozorowski, Namir Shaabani, Irené M. Francino-Urdaniz, Shawn Barman, Oliver Limbo, Alison Burns, Pan-Pan Zhou, Michael J. Ricciardi et al. · 2022 · iScience
  84. A "Made-in-Canada" serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination
    Karen Colwill, Yannick Galipeau, M. Stuible, C. Gervais, C. Arnold, B. Rathod, K. Abe, Jenny H. Wang, A. Pasculescu, Mariam Maltseva et al. · 2021 · medRxiv
  85. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies
    Marina Bubonja‐Šonje, Lara Batičić, Maja Abram, Đurđica Cekinović Grbeša · 2021 · Journal of Virological Methods
  86. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests
    Jamil N. Kanji, Ashley Bailey, Jayne Fenton, Sean H. Ling, Rafael Rivera, Sabrina S. Plitt, Wendy Sligl, Sean C. Taylor, LeeAnn Turnbull, Graham A. Tipples et al. · 2021 · Vaccine
  87. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
    Yi-Nan Zhang, J. Paynter, Cindy Sou, Tatiana Fourfouris, Ying Wang, Ciril Abraham, Timothy A Ngo, Yi Zhang, Lin-Ling He, Jiang Zhu · 2021 · bioRxiv
  88. Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design
    Daojiong Wang, Yushu Ge, Bin Zhong, Dan Liu · 2021 · Computational and Structural Biotechnology Journal
  89. Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics
    J Zhang · 2024 · Heliyon
  90. Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants
    Xiangyang Chi, Lingyun Xia, Guanying Zhang, Ximin Chi, Bangdong Huang, Yuanyuan Zhang, Zhengshan Chen, Jin Han, Liushu Wu, Zeya Li et al. · 2023 · Cell Discovery
  91. Humoral immunity for durable control of SARS-CoV-2 and its variants
    Ryutaro Kotaki, Saya Moriyama, Yoshimasa Takahashi · 2023 · Inflammation and Regeneration
  92. Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component
    Collin Jugler, Hai-Yan Sun, Francisca Grill, K. Kibler, Adrian Esqueda, Hua-Fang Lai, Yi-Ze Li, D. Lake, Qiang Chen · 2022 · Vaccines
  93. Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma
    Ding Yu, Yufeng Li, Hong Liang, Junzheng Wu, Yong Hu, Yan Peng, Taojing Li, Jiawang Hou, Wei-Jing Huang, Li-Dong Guan et al. · 2022 · Advancement of science
  94. Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain
    T. Hancock, Peyton Hickman, Niloo Kazerooni, M. Kennedy, S. Kania, Michelle Dennis, Nicole Szafranski, R. Gerhold, C. Su, Tom J. Masi et al. · 2022 · Journal of Virology
  95. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease
    Pan-Pan Zhou, G. Song, Wan-ting He, N. Beutler, Long-Ping V. Tse, David R. Martinez, A. Schäfer, F. Anzanello, Peter Yong, Linghang Peng et al. · 2022 · bioRxiv
  96. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant
    Nitin K Hingankar, Suprit Deshpande, Payel Das, Zaigham Abbas Rizvi, C. K. Wibmer, Poppy Mashilo, M. Y. Ansari, Alison Burns, Shawn Barman, Fang-Zhu Zhao et al. · 2021 · bioRxiv
  97. Experimental Models for SARS-CoV-2 Infection
    Taewoo Kim, Jeong Seok Lee, Y. Ju · 2021 · Molecules and Cells
  98. Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
    Fang-Zhu Zhao, M. Yuan, Celina Keating, N. Shaabani, Oliver Limbo, Collin Joyce, J. Woehl, Shawn Barman, Alison Burns, Xue-Yong Zhu et al. · 2021 · bioRxiv
  99. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches
    K. Watashi · 2020 · Biochemical and Biophysical Research Communications - BBRC
  100. Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles
    Chengcheng Fan, Jennifer R. Keeffe, Kathryn E. Malecek, Alexander A. Cohen, Anthony P. West, Viren A. Baharani, Annie V. Rorick, Han Gao, Priyanthi N.P. Gnanapragasam, Semi Rho et al. · 2025 · Proceedings of the National Academy of Sciences